US20190292242A1 - Hydrolyzed Jellyfish Collagen Types I, II, and V and Use Thereof - Google Patents
Hydrolyzed Jellyfish Collagen Types I, II, and V and Use Thereof Download PDFInfo
- Publication number
- US20190292242A1 US20190292242A1 US16/372,798 US201916372798A US2019292242A1 US 20190292242 A1 US20190292242 A1 US 20190292242A1 US 201916372798 A US201916372798 A US 201916372798A US 2019292242 A1 US2019292242 A1 US 2019292242A1
- Authority
- US
- United States
- Prior art keywords
- collagen type
- hydrolyzed collagen
- jellyfish
- supplement
- hydrolyzed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/614—Cnidaria, e.g. sea anemones, corals, coral animals or jellyfish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a method of preparation for hydrolyzed collagen type I, II, and V and its use as a therapeutic agent and nutritional supplement.
- Collagen is a complex structural protein which provides strength and flexibility to skin, hair, and nails. Collagen is a major component of muscles, tendons, cartilage, ligaments, joints, and blood vessels. Hydrolyzed coastal jellyfish collagen is extracted from two species of edible jellyfish. The two species, Stomolophus meleagris and Acromitus hardenbergi , contain the highest amount of amino acid collagen types I, II, and V. Type I is primarily found in skin and tendons while type II is primarily found in articular cartilage. Cartilage is unusual in that it has a high proportion of glycine and proline residues. Specifically 4-hydroxyproline and 5-hydroxylysine are found in very few other protein sources, adding benefit to the intake of exogenous collagen.
- U.S. Pat. No. 4,804,745 Koepff et al. discloses agents containing collagen peptides produced by enzymatic hydrolysis for the treatment of degenerative joint diseases. These peptides can be obtained from animal skin, animal bones, and other purified connective tissues. Peptides of this nature have an average molecular weight of 30 to 45 kilodaltons.
- U.S. Pat. No. 5,364,845 Henderson discloses a therapeutic composition and method for the protection, treatment, and repair of connective tissue in mammals comprising glucosamine, chondroitin sulfate, and manganese ascorbate.
- U.S. Pat. No. 5,587,363 to Henderson discloses a therapeutic composition and method for the protection, treatment, and repair of connective tissue in mammals including aminosugars and glycosaminoglycans.
- U.S. Pat. No. 6,025,327 to Alkayali et al. discloses a composition of hydrolyzed collage type II and a method of preparation thereof. The invention is useful in treating cartilage defects.
- U.S. Pat. No. 6,838,440 to Stiles et al. discloses a composition and method of preparation for a desiccated avian sternal cartilage powder and specifically its use in treating arthritic joint cartilage diseases.
- compositions types I, II, and V that may be utilized as a supplement, prophylactic, or treatment for a wide range of conditions.
- the composition should be available for use in a variety of forms for topical or oral administration.
- a jellyfish-derived material comprises hydrolyzed collagen types I, II, and V having an average molecular weight of 4 kilodaltons and 20 kilodaltons.
- the hydrolyzed collagen is sourced from Stomolophus meleagris and Acromitus hardenbergi .
- the hydrolyzed collagen is formulated into a delivery vector comprising one or more gelatin capsules, one or more aqueous solutions, one or more oil suspensions, one or more elixirs, one or more tables, and a powder.
- a method for providing collagen types I, II, and V as a supplement includes administering to an individual a daily dose of a hydrolyzed collagen types I, II, and V, wherein the preferred daily dose is between 1500 mg and 2000 mg.
- the supplement may be formulated as a topical cream, orally administered tablet, or likewise vector.
- FIG. 1 is a schematic diagram of the process for preparing the hydrolyzed jellyfish collagen powder, according to an embodiment of the present invention.
- FIG. 1 Preferred embodiments of the present invention and their advantages may be understood by referring to FIG. 1 , wherein like reference numerals refer to like elements.
- the invention described herein refers to a composition with hydrolyzed collagen types I, II and V sourced from jellyfish, a method for preparing the composition, and use of the composition.
- the method of production involves grinding fresh, frozen, or dehydrated jellyfish.
- the jellyfish are Stomolophus meleagris and Acromitus hardenbergi . These species contain the highest levels of collagen type I, II, and V.
- the bell and oral arms are isolated from the jellyfish wherein high concentrations of collages types I, II, and V exist.
- Prior art involves cutting and separating meat and bone from the carcass of an animal such as a chicken. Jellyfish are a preferred source as they do not contain bone, brain, or a heart.
- step 5 fresh, frozen, or dehydrated jellyfish are sourced and the bell and oral arms are separated.
- a final composition of 50% Stomolophus meleagris and 50% Acromitus hardenbergi is processed by grinding each of the components together.
- step 10 the ground jellyfish are suspended and incubated in an aqueous solution, preferably water, for 24 hours at a temperature of 35° C. at a pH between about 4 and 8. The grinding of the jellyfish allows for the salt removal and washing process to be more efficient.
- the suspension and incubation period is repeated three times to remove salt from the suspension.
- step 15 the water is removed from the suspension leaving the jellyfish particulates behind for purification.
- Enzymatic hydrolysation is obtained by incubating the jellyfish with one or more proteases under pH and temperature control to form a hydrolysate.
- the overall range of molecular weight is between 4 kilodaltons and 20 kilodaltons. In a preferred embodiment, the molecular weight of the product is between 15 kilodaltons and 20 kilodaltons.
- the protease may include pancreatin, papain, ficin, or bromelain and are preferentially sourced sustainably.
- the pH will depend on the optimum activation pH of the specific enzyme used for the hydrolysation as known in the art. In a preferred embodiment, the protease enzyme pancreatin is used at a pH between 7.5 and 8.
- the protease is effective at a temperature between 45° C. and 50° C. At this pH and temperature range an incubation period of 12 hours is used.
- the hydrolysate is sterilized for 30 minutes at a temperature between 95° C. and 105° C.
- the protease enzyme papain is used at pH between 6 and 6.5. At this pH, the papain is effective at a temperature between 52° C. and 57° C. At this pH and temperature range, an incubation period of 8 hours is used.
- the sterilized hydrolysate is filtered through diatomaceous earth, concentrated under vacuum, dried to form the powder, and packaged for retail, consumption, storage, or otherwise.
- the vacuum concentrated hydrolysate is spray dried through a size 56 pressure nozzle into a heat tunnel.
- the final particle size and mesh are adjusted to 0.46 g/cc, which will result in a fine powder.
- the fine powder is comprised of collagen types I, II, and V, as well as a blend of other amino acids present in the jellyfish oral arms and bell.
- the powder may then be packed in a 40 kg drum having a plastic bag liner. This process yields a water soluble product.
- the amino acid composition of the final hydrolysate of types I, II, and V collagen is shown below in Table 1.
- the amino acid composition of the hydrolysate may differ substantially from typical collagens.
- the composition and molecular weights of the peptides allow for an increase in the bio-assimilation of the peptides.
- Table 2 shows the mineral content of the final composition.
- the final composition is composed of 30% to 40% collagen peptides, and 30% to 35% minerals such as calcium, potassium, sodium, iron, zinc, sulfur, magnesium, copper, phosphorous, manganese, and chloride.
- the average molecular weight of the product is between 15 kilodaltons and 20 kilodaltons.
- the final moisture content is between 2% and 5%.
- the final product is high in mucopolysaccharides, particularly chondroitin sulfate and glucosamine sulfate as shown in Table 3.
- hydrolyzed jellyfish collagen is beneficial in promoting brain function in age related neurological diseases.
- Oral administration may include oral, enteral, or intragastic administration.
- Several other research studies have shows benefits in reversing photo-aging, reducing fatigue, preventing arthritis, and reducing cell oxidation.
- the immune system is stimulated along with an increase in neurological activities.
- the targeted molecular weight range of 4 kilodaltons to 20 kilodaltons allows for the human body to easily assimilate the essential nutrient presents in the composition.
- Type I collagen is the most abundant collagen in the human body. It is used in treating conditions of the bone and skin. Type II collagen is found in joint cartilage. Its oral ingestions appears to reduce autoimmunity resulting in reduced inflammation in instances of osteoarthritis and rheumatism. Other forms of connective tissue disorders have been greatly benefitted by type II collagen. Type V collagen has been associated with Ehlers-Danlos syndrome as well as other genetic and non-genetic connective tissue disorders.
- the composition may be taken as a nutritional supplement, prophylactic agent, or therapeutic.
- Oral administration may be accomplished by taking a powder, tablet, oil emulsion, aqueous or oil suspension, hard or soft capsule, syrup, tincture, or elixir.
- Each of these embodiments may be formed by a method known in the art for the manufacture of pharmaceutical, nutraceutical, or supplemental agents.
- the final product may contain artificial or natural sweeteners, flavoring agents, coloring agents, binding agents, thickening agents, emulsifiers, and preservatives. Any of these ingredients, and the combination thereof may increase the palatability of the composition.
- Binding agents may include starch, gelatin and acacia.
- Granulating and disintegrating agents may include corn starch and alginic acid.
- Lubricating agents may also be included including magnesium stearate, stearic acid, and talc.
- adjuvants as known in the art may be added to increase the bio-availability of the composition.
- inert excipients may be used as known in the art. Excipients may include calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate. If a tablet form is used, the tablets may be instantized, or time buffered by adjusting the coating of the tablet. Time buffering materials such as wax, glyceryl monostearate, or glyceryl distearate may be used. In further embodiment, enteric coatings may be used. In further embodiments, the composition may take forms as found in the cosmetic industry, such as facial creams, body lotions, lip sticks, and other skin topical treatments.
- mixing the active ingredients of the composition with an inert solid diluent may produce hard capsules as known in the art.
- the inert solid diluent may include calcium carbonate, calcium phosphate, and kaolin.
- Soft gel formulations may include mixing the active ingredients of the composition with water or an oil medium.
- Aqueous suspensions may be produced as known in the art through the utilization of suspending agents, dispersing agents, wetting agents, among others known in the art.
- Sweetening agents may be used as known in the art, including sucrose or saccharin.
- Oil suspensions may be formulated by suspending the active ingredients of the composition in one or a combination of oils known in the art.
- Oil suspensions may contain a thickening agent such as waxes, hard paraffin, or cetyl alcohol. Oils used may be vegetable oil, coconut oil, arachis oil, mineral oil, or others.
- Syrups and elixirs may be formulated with sweeting agents, demulcents, preservatives, flavoring agents, and coloring agents as known in the art.
- a preferred embodiment involves combining the hydrolyzed collagen powder with an acid fruit juice prior to oral administration. Further, the fruit juice may be foregone by the user of powdered ascorbic acid mixed with the active ingredients of the composition in a tablet.
- the active ingredients are formulated in one or more of the above-mentioned embodiments.
- the composition is administered orally as a nutritional supplement.
- the hydrolyzed collagen is administered at a daily dosage of 200 mg to 5000 mg. In a preferred embodiment, the effective daily dose is between 1500 mg and 2000 mg.
- the hydrolyzed collagen is taken on an empty stomach with a beverage containing ascorbic acid (vitamin C). In a preferred embodiment, the hydrolyzed collagen is mixed with the ascorbic acid containing beverage prior to administration of the mixture.
Abstract
Hydrolyzed collagen types I, II, and V powder compositions, method of preparing the compositions, and use of the compositions in treating a variety of ailments. The compositions are topically or orally administered to an individual at a daily dosage between 1500 mg and 2000 mg.
Description
- The present invention relates to a method of preparation for hydrolyzed collagen type I, II, and V and its use as a therapeutic agent and nutritional supplement.
- Collagen is a complex structural protein which provides strength and flexibility to skin, hair, and nails. Collagen is a major component of muscles, tendons, cartilage, ligaments, joints, and blood vessels. Hydrolyzed coastal jellyfish collagen is extracted from two species of edible jellyfish. The two species, Stomolophus meleagris and Acromitus hardenbergi, contain the highest amount of amino acid collagen types I, II, and V. Type I is primarily found in skin and tendons while type II is primarily found in articular cartilage. Cartilage is unusual in that it has a high proportion of glycine and proline residues. Specifically 4-hydroxyproline and 5-hydroxylysine are found in very few other protein sources, adding benefit to the intake of exogenous collagen.
- U.S. Pat. No. 4,804,745 Koepff et al. discloses agents containing collagen peptides produced by enzymatic hydrolysis for the treatment of degenerative joint diseases. These peptides can be obtained from animal skin, animal bones, and other purified connective tissues. Peptides of this nature have an average molecular weight of 30 to 45 kilodaltons.
- U.S. Pat. No. 5,399,347 Trentham et al. and Trentham et al. (science 261:1727-1729, 1993) disclose the effective treatment of rheumatoid arthritis with water-soluble whole chicken collagen type II or biologically active peptides derived therefrom.
- U.S. Pat. No. 5,364,845 Henderson discloses a therapeutic composition and method for the protection, treatment, and repair of connective tissue in mammals comprising glucosamine, chondroitin sulfate, and manganese ascorbate. U.S. Pat. No. 5,587,363 to Henderson discloses a therapeutic composition and method for the protection, treatment, and repair of connective tissue in mammals including aminosugars and glycosaminoglycans.
- U.S. Pat. No. 6,025,327 to Alkayali et al. discloses a composition of hydrolyzed collage type II and a method of preparation thereof. The invention is useful in treating cartilage defects.
- U.S. Pat. No. 6,838,440 to Stiles et al. discloses a composition and method of preparation for a desiccated avian sternal cartilage powder and specifically its use in treating arthritic joint cartilage diseases.
- Several research studies on hydrolyzed jellyfish collagen have been conducted in vivo showing positive health benefits such as improved brain function, reversal of photo-aging, fatigue reduction, arthritis prevention, and reduced cellular oxidation. Further, collagen helps to stimulate the immune system and neurological activities.
- Based on the foregoing, there is a need in the art for a new composition of collagens types I, II, and V that may be utilized as a supplement, prophylactic, or treatment for a wide range of conditions. The composition should be available for use in a variety of forms for topical or oral administration.
- A jellyfish-derived material comprises hydrolyzed collagen types I, II, and V having an average molecular weight of 4 kilodaltons and 20 kilodaltons. Preferentially, the hydrolyzed collagen is sourced from Stomolophus meleagris and Acromitus hardenbergi. The hydrolyzed collagen is formulated into a delivery vector comprising one or more gelatin capsules, one or more aqueous solutions, one or more oil suspensions, one or more elixirs, one or more tables, and a powder.
- A method for providing collagen types I, II, and V as a supplement includes administering to an individual a daily dose of a hydrolyzed collagen types I, II, and V, wherein the preferred daily dose is between 1500 mg and 2000 mg. The supplement may be formulated as a topical cream, orally administered tablet, or likewise vector.
- The foregoing, and other features and advantages of the invention, will be apparent from the following, more particular description of the preferred embodiments of the invention, the accompanying drawings, and the claims.
- For a more complete understanding of the present invention, the objects and advantages thereof, reference is now made to the ensuing descriptions taken in connection with the accompanying drawings briefly described as follows.
-
FIG. 1 is a schematic diagram of the process for preparing the hydrolyzed jellyfish collagen powder, according to an embodiment of the present invention. - Preferred embodiments of the present invention and their advantages may be understood by referring to
FIG. 1 , wherein like reference numerals refer to like elements. - In general, the invention described herein refers to a composition with hydrolyzed collagen types I, II and V sourced from jellyfish, a method for preparing the composition, and use of the composition. The method of production involves grinding fresh, frozen, or dehydrated jellyfish. In a preferred embodiment, the jellyfish are Stomolophus meleagris and Acromitus hardenbergi. These species contain the highest levels of collagen type I, II, and V. The bell and oral arms are isolated from the jellyfish wherein high concentrations of collages types I, II, and V exist. Prior art involves cutting and separating meat and bone from the carcass of an animal such as a chicken. Jellyfish are a preferred source as they do not contain bone, brain, or a heart. They are comprised of 5% solid matter and 95% water making the isolation of proteins a more simple process. Standard GMP processes are used throughout the entire process to produce a powdered collagen types I, II, and V supplement for oral, topical, or likewise administration. The powder will be a blend of amino acids present
- The production of hydrolyzed jellyfish collagen in powdered form is shown in
FIG. 1 . In step 5, fresh, frozen, or dehydrated jellyfish are sourced and the bell and oral arms are separated. A final composition of 50% Stomolophus meleagris and 50% Acromitus hardenbergi is processed by grinding each of the components together. In step 10, the ground jellyfish are suspended and incubated in an aqueous solution, preferably water, for 24 hours at a temperature of 35° C. at a pH between about 4 and 8. The grinding of the jellyfish allows for the salt removal and washing process to be more efficient. The suspension and incubation period is repeated three times to remove salt from the suspension. In step 15, the water is removed from the suspension leaving the jellyfish particulates behind for purification. Enzymatic hydrolysation is obtained by incubating the jellyfish with one or more proteases under pH and temperature control to form a hydrolysate. The overall range of molecular weight is between 4 kilodaltons and 20 kilodaltons. In a preferred embodiment, the molecular weight of the product is between 15 kilodaltons and 20 kilodaltons. The protease may include pancreatin, papain, ficin, or bromelain and are preferentially sourced sustainably. The pH will depend on the optimum activation pH of the specific enzyme used for the hydrolysation as known in the art. In a preferred embodiment, the protease enzyme pancreatin is used at a pH between 7.5 and 8. At this pH the protease is effective at a temperature between 45° C. and 50° C. At this pH and temperature range an incubation period of 12 hours is used. In step 20, the hydrolysate is sterilized for 30 minutes at a temperature between 95° C. and 105° C. In another preferred embodiment, the protease enzyme papain is used at pH between 6 and 6.5. At this pH, the papain is effective at a temperature between 52° C. and 57° C. At this pH and temperature range, an incubation period of 8 hours is used. In steps 25 to 40, the sterilized hydrolysate is filtered through diatomaceous earth, concentrated under vacuum, dried to form the powder, and packaged for retail, consumption, storage, or otherwise. In an alternative embodiment, other methods of filtration, such as vacuum filtration may be used. In a preferred embodiment, the vacuum concentrated hydrolysate is spray dried through a size 56 pressure nozzle into a heat tunnel. The final particle size and mesh are adjusted to 0.46 g/cc, which will result in a fine powder. The fine powder is comprised of collagen types I, II, and V, as well as a blend of other amino acids present in the jellyfish oral arms and bell. The powder may then be packed in a 40 kg drum having a plastic bag liner. This process yields a water soluble product. - The amino acid composition of the final hydrolysate of types I, II, and V collagen is shown below in Table 1. The amino acid composition of the hydrolysate may differ substantially from typical collagens. The composition and molecular weights of the peptides allow for an increase in the bio-assimilation of the peptides. Table 2 shows the mineral content of the final composition. In a preferred embodiment, the final composition is composed of 30% to 40% collagen peptides, and 30% to 35% minerals such as calcium, potassium, sodium, iron, zinc, sulfur, magnesium, copper, phosphorous, manganese, and chloride.
-
TABLE 1 ASPARTIC ACID 2.99% THREONINE 2.32% SERINE 1.56% GLUTAMIC ACID 5.77% PROLINE 3.72% GLYCINE 6.79% ALANINE 3.64% CYSTINE 0.36% VALINE 1.09% METHIONINE 0.47% ISOLEUCINE 1.41% LEUCINE 1.94% TYROSINE 0.76% PHENYLALANINE 0.52% LYSINE (TOTAL) 1.87% HISTIDINE 0.24% ARGININE 2.84% TRYPTOPHAN 0.14% TOTAL 38.43% -
TABLE 2 CALCIUM 0.43% POTASSIUM 0.435% SODIUM 10.6% IRON 0.00284% ZINC 0.0035% SULFUR 2.22% MAGNESIUM 1.08% COPPER 0.0004% PHOSPHOROUS 0.155% MANGANESE 0.0% CHLORIDE 17.1% TOTAL 32.02674% - In an embodiment, the average molecular weight of the product is between 15 kilodaltons and 20 kilodaltons. In a preferred embodiment, the final moisture content is between 2% and 5%. The final product is high in mucopolysaccharides, particularly chondroitin sulfate and glucosamine sulfate as shown in Table 3.
-
TABLE 3 CHONDROITIN SULFATE 10.59% HYALURONIC ACID 3.21% MUCOPOLYSACCARIDE 29.4% GLUCOSOMINE 0.19% TOTAL 38.43% - When taken orally, research shown that hydrolyzed jellyfish collagen is beneficial in promoting brain function in age related neurological diseases. Oral administration may include oral, enteral, or intragastic administration. Several other research studies have shows benefits in reversing photo-aging, reducing fatigue, preventing arthritis, and reducing cell oxidation. Furthermore, the immune system is stimulated along with an increase in neurological activities. The targeted molecular weight range of 4 kilodaltons to 20 kilodaltons allows for the human body to easily assimilate the essential nutrient presents in the composition.
- Type I collagen is the most abundant collagen in the human body. It is used in treating conditions of the bone and skin. Type II collagen is found in joint cartilage. Its oral ingestions appears to reduce autoimmunity resulting in reduced inflammation in instances of osteoarthritis and rheumatism. Other forms of connective tissue disorders have been greatly benefitted by type II collagen. Type V collagen has been associated with Ehlers-Danlos syndrome as well as other genetic and non-genetic connective tissue disorders. Various types of collagen have been found to reduce wrinkles, support re-growth of joint tissue, relieve joint pain, prevent osteoporosis, reduce cellulite, prevent stretch marks, aid in weight loss, detoxify the liver, repair leaky gut syndrome, support healthy hair growth, grow stronger nails, support healthy teeth, balance hormones, alleviate anxiety, promote restful sleep, prevent atherosclerosis, increase brain function, among many more benefits. Supplementing hydrolyzed collagen types I, II, and V can effectively be accomplished by oral ingestion or topical application depending on the desired result.
- The composition may be taken as a nutritional supplement, prophylactic agent, or therapeutic. Oral administration may be accomplished by taking a powder, tablet, oil emulsion, aqueous or oil suspension, hard or soft capsule, syrup, tincture, or elixir. Each of these embodiments may be formed by a method known in the art for the manufacture of pharmaceutical, nutraceutical, or supplemental agents. The final product may contain artificial or natural sweeteners, flavoring agents, coloring agents, binding agents, thickening agents, emulsifiers, and preservatives. Any of these ingredients, and the combination thereof may increase the palatability of the composition. Binding agents may include starch, gelatin and acacia. Granulating and disintegrating agents may include corn starch and alginic acid. Lubricating agents may also be included including magnesium stearate, stearic acid, and talc. Furthermore, adjuvants as known in the art may be added to increase the bio-availability of the composition. Further, inert excipients may be used as known in the art. Excipients may include calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate. If a tablet form is used, the tablets may be instantized, or time buffered by adjusting the coating of the tablet. Time buffering materials such as wax, glyceryl monostearate, or glyceryl distearate may be used. In further embodiment, enteric coatings may be used. In further embodiments, the composition may take forms as found in the cosmetic industry, such as facial creams, body lotions, lip sticks, and other skin topical treatments.
- In oral use formulations, mixing the active ingredients of the composition with an inert solid diluent may produce hard capsules as known in the art. The inert solid diluent may include calcium carbonate, calcium phosphate, and kaolin. Soft gel formulations may include mixing the active ingredients of the composition with water or an oil medium.
- Aqueous suspensions may be produced as known in the art through the utilization of suspending agents, dispersing agents, wetting agents, among others known in the art. Sweetening agents may be used as known in the art, including sucrose or saccharin.
- Oil suspensions may be formulated by suspending the active ingredients of the composition in one or a combination of oils known in the art. Oil suspensions may contain a thickening agent such as waxes, hard paraffin, or cetyl alcohol. Oils used may be vegetable oil, coconut oil, arachis oil, mineral oil, or others.
- Syrups and elixirs may be formulated with sweeting agents, demulcents, preservatives, flavoring agents, and coloring agents as known in the art.
- Research studies show that ascorbic acid found in fruit juices promotes the formation of connective tissues when combined with hydrolyzed collagen powder. For this reason, a preferred embodiment involves combining the hydrolyzed collagen powder with an acid fruit juice prior to oral administration. Further, the fruit juice may be foregone by the user of powdered ascorbic acid mixed with the active ingredients of the composition in a tablet.
- In a preferred embodiment, the active ingredients are formulated in one or more of the above-mentioned embodiments. The composition is administered orally as a nutritional supplement. The hydrolyzed collagen is administered at a daily dosage of 200 mg to 5000 mg. In a preferred embodiment, the effective daily dose is between 1500 mg and 2000 mg. In another preferred embodiment, the hydrolyzed collagen is taken on an empty stomach with a beverage containing ascorbic acid (vitamin C). In a preferred embodiment, the hydrolyzed collagen is mixed with the ascorbic acid containing beverage prior to administration of the mixture.
- The invention has been described herein using specific embodiments for the purposes of illustration only. It will be readily apparent to one of ordinary skill in the art, however, that the principles of the invention can be embodied in other ways. Therefore, the invention should not be regarded as being limited in scope to the specific embodiments disclosed herein, but instead as being fully commensurate in scope with the following claims.
Claims (13)
1. A method of providing collagen type I, collagen type II, and collagen type V as a supplement comprising:
a. administering to an individual an effective daily dose of a jellyfish derived material, and wherein the jellyfish derived material comprises hydrolyzed collagen type I, hydrolyzed collagen type II, and hydrolyzed collagen type V.
2. The method of claim 1 wherein the jellyfish-derived material derived from a group of jellyfish species comprising Stomolophus meleagris and Acromitus hardenbergi.
3. The method of claim 1 wherein each of the hydrolyzed collagen type I, hydrolyzed collagen type II, and hydrolyzed collagen type V have an average molecular weight between 4 kilodaltons and 20 kilodaltons.
4. The method of claim 3 wherein each of the hydrolyzed collagen type I, hydrolyzed collagen type II, and Hydrolyzed collagen type V have an average molecular weight between 15 kilodaltons and 20 kilodaltons.
5. The method of claim 1 , wherein the supplement is administered and formulated as a topical cream.
6. The method of claim 5 , wherein the topical cream prevents an ailment comprising; neurodegenerative disease, degenerative joint diseases, joint defects, osteoarthritis, vascular disease, fatigue, cell oxidation, photo-aging, skin conditions, calcium binding proteins, memory loss, and decreased brain function.
7. The method of claim 5 , wherein an effective daily amount is between 200 mg and 5000 mg.
8. The method of claim 5 , wherein the effective daily amount is between 1500 mg and 2000 mg.
9. The method of claim 1 wherein the supplement is orally administered.
10. The method of claim 9 , wherein the orally administered supplement is a formulation comprising; one or more gelatin capsules, one or more aqueous suspensions, one or more oil suspensions, one or more elixirs, one or more tablets, and a powder.
11. The method of claim 10 , wherein the orally administered supplement prevents an ailment comprising; neurodegenerative disease, degenerative joint diseases, joint defects, osteoarthritis, vascular disease, fatigue, cell oxidation, photo-aging, skin conditions, calcium binding proteins, memory loss, and decreased brain function.
12. The method of claim 10 , wherein the effective daily does is between 200 mg and 5000 mg.
13. The method of claim 10 , wherein the effective daily does is between 1500 mg and 2000 mg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/372,798 US20190292242A1 (en) | 2017-02-22 | 2019-04-02 | Hydrolyzed Jellyfish Collagen Types I, II, and V and Use Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/439,094 US10287339B2 (en) | 2017-02-22 | 2017-02-22 | Hydrolyzed jellyfish collagen types I, II, and V and use thereof |
US16/372,798 US20190292242A1 (en) | 2017-02-22 | 2019-04-02 | Hydrolyzed Jellyfish Collagen Types I, II, and V and Use Thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/439,094 Division US10287339B2 (en) | 2017-02-22 | 2017-02-22 | Hydrolyzed jellyfish collagen types I, II, and V and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190292242A1 true US20190292242A1 (en) | 2019-09-26 |
Family
ID=63166960
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/439,094 Active US10287339B2 (en) | 2017-02-22 | 2017-02-22 | Hydrolyzed jellyfish collagen types I, II, and V and use thereof |
US16/372,798 Abandoned US20190292242A1 (en) | 2017-02-22 | 2019-04-02 | Hydrolyzed Jellyfish Collagen Types I, II, and V and Use Thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/439,094 Active US10287339B2 (en) | 2017-02-22 | 2017-02-22 | Hydrolyzed jellyfish collagen types I, II, and V and use thereof |
Country Status (2)
Country | Link |
---|---|
US (2) | US10287339B2 (en) |
CN (1) | CN108456248B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110691604A (en) * | 2017-03-15 | 2020-01-14 | 罗赛洛公司 | Compositions and methods for hydrolyzing collagen peptides and commensal microorganisms |
US11732015B2 (en) * | 2018-12-13 | 2023-08-22 | Ahmad Alkayali | Method of drying jellyfish matter |
US11759479B2 (en) * | 2021-04-02 | 2023-09-19 | Ohm Creations, LLC | Compositions comprising a manganese mineral and methods of use |
CN113318003A (en) * | 2021-04-08 | 2021-08-31 | 海臻(上海)生物科技有限公司 | Jellyfish polypeptide and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6894029B1 (en) * | 2000-11-13 | 2005-05-17 | Auburn University | Use of jellyfish collagen (type II) in the treatment of rheumatoid arthritis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6337389B1 (en) * | 1995-03-17 | 2002-01-08 | Bioscience Consultants, L.L.C. | Method and process for the production of collagen preparations from invertebrate marine animals and compositions thereof |
CN1721546A (en) * | 2004-07-12 | 2006-01-18 | 周立军 | Process for preparing II-type collagen compound |
CN101234126A (en) * | 2007-11-28 | 2008-08-06 | 张丽丽 | Collagen peptide of Jellyfish with anti-fatigue active and preparation technique thereof |
CN101245095A (en) * | 2008-01-10 | 2008-08-20 | 中国海洋大学 | Extraction of jellyfish collagen and method for producing collagen peptide |
CN103882082B (en) * | 2014-02-26 | 2016-07-20 | 江苏大学 | A kind of I type and the preparation method of collagen type v albumen |
CN104212864A (en) * | 2014-08-22 | 2014-12-17 | 青岛龙宫海洋牧场生态修复工程有限公司 | Extraction process of jellyfish active collagen hydrolysate |
-
2017
- 2017-02-22 US US15/439,094 patent/US10287339B2/en active Active
- 2017-11-22 CN CN201711177638.2A patent/CN108456248B/en active Active
-
2019
- 2019-04-02 US US16/372,798 patent/US20190292242A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6894029B1 (en) * | 2000-11-13 | 2005-05-17 | Auburn University | Use of jellyfish collagen (type II) in the treatment of rheumatoid arthritis |
Non-Patent Citations (2)
Title |
---|
Bello et al., "Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature", Current Medical Research and Opinion, 2006, pp. 2221-2232 (Year: 2006) * |
Ucar et al., "Collagen for brain repair: therapeutic perspectives", Neural Regeneration Research, 2018, pp. 595-598 (Year: 2018) * |
Also Published As
Publication number | Publication date |
---|---|
US10287339B2 (en) | 2019-05-14 |
CN108456248A (en) | 2018-08-28 |
US20180237498A1 (en) | 2018-08-23 |
CN108456248B (en) | 2021-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6323319B1 (en) | Method of making hydrolyzed collagen type II | |
US20190292242A1 (en) | Hydrolyzed Jellyfish Collagen Types I, II, and V and Use Thereof | |
US6780841B2 (en) | Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same | |
Khora | Marine fish-derived bioactive peptides and proteins for human therapeutics | |
CA2435392C (en) | Desiccated avian sternal cartilage powder | |
KR101132392B1 (en) | Fermented Placenta Compositin and Use Thereof | |
KR101156703B1 (en) | Egg-derived bone-strengthening composition | |
JPWO2005077349A1 (en) | Human β-defensin production promoter | |
CN101219211A (en) | Compound polypeptide composition, preparing method and uses of the same | |
WO2020018504A1 (en) | Collagen and cell matter supplement and method for administering same | |
JP2015096476A (en) | Composition for collagen production promotion, composition for collagen absorption promotion, and composition for anti-obesity | |
JP2017048244A (en) | Composition for collagen production promotion, composition for collagen absorption promotion, and composition for anti-obesity | |
JP2018030880A (en) | Cartilage formation promotor | |
EP0682873B1 (en) | Proteinhydrolysate from marine animals, process for obtaining and applications | |
EP0073173A1 (en) | Products extracted from invertebrate sea-animals, their preparation and their uses in dietetics,pharmaceutics and cosmetology | |
RU2713935C1 (en) | Peptides of marine origin and fish nucleotides, compositions and use thereof for reducing blood glucose | |
JP4115561B2 (en) | Hair growth promoter | |
KR20050003989A (en) | Egg derivatives having bone-strengthening effects | |
Дзюба et al. | COLLAGEN HYDROLYZATE AS COMPONENT OF FOODSTUFFS OF HEALTH NUTRITION | |
JP2002114694A (en) | Blood cholesterol lowering composition | |
JP2019054769A (en) | Food for hair graying suppression | |
RU2161002C1 (en) | Food, general-restorative, treatment-and-prophylactic product from shark tissues and method of its production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |